Latest news with #HPP
Yahoo
29-05-2025
- Business
- Yahoo
Leeward CC's Food Innovation Hub to Host Hawai'i High Pressure Processing Summit
Event to showcase Hiperbaric cold processing technology for safer, quality, clean-label foods WAHIAWĀ, Hawaiʻi, May 29, 2025 /PRNewswire/ -- Leeward Community College's Wahiawā Value-Added Product Development Center (WVAPDC) is pushing Hawaiʻi into the future of food preservation with the launch of the state's first High Pressure Processing (HPP) Summit. Taking place on Thursday, July 17 in partnership with Hiperbaric, the global leader in HPP technology, the summit will bring local producers, food and beverage entrepreneurs, scientists, and industry leaders to the WVAPDC for a deep dive into the transformative benefits of HPP — a method that enhances food safety, extends shelf life, and supports the development of minimally processed, preservative-free products. "As the only facility in Hawaiʻi equipped with an HPP machine, we are thrilled to open our doors and share how this technology can revolutionize the way our food is made, packaged, and preserved," said Chris Bailey, WVAPDC manager. "This summit is about empowering local food producers with the tools and knowledge to scale high-quality, locally made products for Hawaiʻi and beyond." HPP is a non-thermal food preservation method that uses extremely high water pressure to inactivate harmful pathogens and spoilage microorganisms in food. In a matter of minutes, this process extends shelf life while preserving food's freshness, flavor, and nutritional quality – all without the need for preservatives and additives. To explore these benefits in greater detail, summit attendees can engage with expert panels, live demonstrations, and networking opportunities that offer hands-on insights into HPP and its impact. "Hiperbaric is proud to partner with Leeward Community College and the WVAPDC for Hawaiʻi's first High Pressure Processing Summit," said Rob Peregrina, Hiperbaric USA executive director. "This milestone event highlights the cutting-edge capabilities of our HPP technology. It also underscores our shared commitment to food innovation, safety, and sustainability while empowering Hawaiʻi's food entrepreneurs to elevate local products to national and global markets." Summit sessions will cover HPP-ready packaging and real-world applications, food safety, regulatory compliance, and success stories from Hawaiʻi food entrepreneurs who scaled their businesses with support from the WVAPDC. The event boasts an impressive speaker lineup, with experts in food science, entrepreneurship and policy, including: Chris Bailey, WVAPDC manager; Hawaiʻi State Senator Donovan M. Dela Cruz; Dr. Mario González-Angulo, Hiperbaric HPP applications manager; Dr. Carlos Peñaloza, Leeward Community College chancellor; Daniela Soto Castro, Hiperbaric HPP applications specialist; Anthony Zapata, Hiperbaric business development manager; and Hailey Zhou, WVAPDC product development manager. "This summit highlights Leeward's commitment to equipping Hawaiʻi's food innovators with state-of-the-art technology that enables them to expand into new markets with an extended shelf-life and premium offering," said Carlos Peñaloza, Leeward Community College chancellor. "By partnering with industry leaders like Hiperbaric, we are helping our local entrepreneurs compete globally while building a stronger, more resilient food economy at home." "The summit is a monumental step toward unlocking the full potential of the WVAPDC," said State Senator Donovan M. Dela Cruz. "By showcasing the Center's HPP technology and value-added services, we are reinforcing our commitment to regional economic development. These strategic investments empower local entrepreneurs and small businesses to compete effectively in both domestic and international markets." Tickets for the Hawaiʻi High Pressure Processing Summit are available at different rates. A $100 Early Bird Special will be offered through June 15, while General Admission will be $200 from June 16 to July 16. All participants must register individually at Media kit linked here HPP Machine Photos & B-Roll (Courtesy of Hiperbaric) Speaker headshots & bios (Courtesy of Leeward Community College) Event flyer (Courtesy of Leeward Community College) About the Wahiawā Value-Added Product Development Center Established in 2024, the Wahiawā Value-Added Product Development Center (WVAPDC) is a 33,000-square-foot food manufacturing and education facility operated by Leeward Community College in partnership with the State of Hawaiʻi. WVAPDC plays a key role in strengthening Hawaiʻi's economy by helping to turn local ingredients into value-added food products for local and global markets. The Center accomplishes this mission by supporting students, food entrepreneurs, and farmers through premier educational programming, product development consulting, and access to comprehensive resources – including commercial kitchens with state-of-the-art equipment, a product development lab with testing capabilities, and the state's only Hiperbaric high pressure processing system for small-scale production. The Center also offers packaging and labeling suites, flexible workspaces for classes and training, and an event loft with a demonstration kitchen. For more information, visit our website, subscribe to our mailing list, or follow us on Instagram for updates and events. About HiperbaricHiperbaric is the global leader in high pressure technology, designing, manufacturing, and marketing its HPP equipment internationally. The company is recognized for its reliability, customer support, and continuous R&D. With more than 400 installations, hundreds of companies worldwide use Hiperbaric equipment for the processing of juices and beverages, meat, fish and shellfish, fruits and vegetables, dairy and prepared dishes. A highly versatile technology, HPP can be applied to a wide range of foods. Hiperbaric is headquartered in Burgos, Spain, with a U.S. office in Miami, FL, an Asia office in Shanghai, China, and commercial and technical offices in Mexico and Oceania. For more information, visit: MEDIA CONTACTS:Devon Bedoya Anthony Zapata Marketing Specialist Business Development Manager Leeward Community College Hiperbaric dbedoya@ Mobile: (203) 570-3953 Mobile: (305) 746-0209 View original content to download multimedia: SOURCE Hiperbaric Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
17-05-2025
- Business
- Business Wire
Be Biopharma Announces New Preclinical Data for BE-102, a B Cell Medicine for the Potential Treatment of Hypophosphatasia
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Be Biopharma, Inc. ('Be Bio'), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today presented results from new preclinical research demonstrating a single administration of BE-102, a BCM for the potential treatment for Hypophosphatasia (HPP), produces continuous levels of active ALP long-term in vivo. The findings will be presented during an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 28 th Annual Meeting on Saturday, May 17, at 10:45 AM CT. HPP is a genetic disease caused by deficient ALP activity, resulting from pathogenic mutations in the ALPL gene, which leads to multi-systemic clinical complications including deficient bone mineralization. Enzyme replacement therapy (ERT) is the only approved treatment for HPP which requires frequent lifelong injections, and is only available for perinatal/infantile- and juvenile-onset forms of HPP. BE-102 was developed to address these limitations by providing continuous secretion of active ALP from a single infusion, with the flexibility to be titratable and re-dosable as needed. BE-102 is manufactured from primary human B cells by isolating, activating, and precision engineering with CRISPR/Cas9 followed by AAV-mediated delivery of a DNA donor template for the insertion of human ALPL gene into the CCR5 locus (a safe harbor locus) followed by expansion and differentiation in culture into ALP-secreting B lymphocyte lineage cells. 'These studies demonstrate the potential of our B cell medicine platform to deliver B cell derived active ALP with durability out to six months,' said Rick Morgan, Chief Scientific Officer of Be Biopharma. 'BE-102 offers a novel and durable approach that may overcome the limitations of current enzyme therapy and does not require pre-conditioning, offering flexibility for re-dosing.' The presentation highlights both in vivo and in vitro data supporting the target product profile for BE-102. In vivo studies were conducted in immune-deficient NOG-hIL6 mice, confirming long-term engraftment and continuous production of B cell derived active ALP (>175 days) following a single IV administration of BE-102. No BE-102 related adverse events have been observed across multiple in vivo studies. In vitro pharmacology data presented today demonstrates that BE-102 secretes active ALP, which is capable of rescuing calcium deposit inhibited by inorganic pyrophosphate (PPi), a potent inhibitor of bone mineralization and an ALP substrate which accumulates in people with HPP. Be Bio's in vitro and in vivo pharmacology and safety data established preclinical proof-of-concept that BE-102 has the potential to be a disease-modifying therapy for people with HPP by providing continuous secretion of ALP, with the flexibility to be titratable and re-dosable as needed. A robust package of preclinical studies is planned in anticipation of submission of an IND for a first-in-human clinical trial for people with HPP. About BE-102 BE-102 is a first-in-class BCM that has been engineered using artificial intelligence-guided protein design to modify primary human B cells to produce ALP, an enzyme deficient in people living with HPP. A single infusion of BE-102 has the potential to provide continuous secretion of therapeutic ALP with the flexibility to be titrated and/or re-dosed, if needed, and without the need for pre-conditioning. BE-102 has been selected as a Development Candidate and has the potential to transform the standard of care for people living with HPP. About Engineered B Cell Medicines – A New Class of Cellular Medicines The B cell is a powerful cell that produces thousands of proteins per cell per second at constant levels, and over decades. Precision genome editing can now be used to engineer B Cells that produce therapeutic proteins of interest, driving a new class of cellular medicines – Engineered B Cell Medicines (BCMs) – with the potential to be durable, allogeneic, re-dosable, and administered without pre-conditioning. The promise of BCMs could transform therapeutic biologics with broad application — across protein classes, patient populations and therapeutic areas. About Be Biopharma Be Biopharma ('Be Bio') is pioneering Engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to create a bold new class of cell therapies. Be Bio was founded in October 2020, and is backed by ARCH Venture Partners, Atlas Venture, RA Capital Management, Nextech, Alta Partners, Longwood Fund, Bristol Myers Squibb, Takeda Ventures, Seattle Children's Research Institute, Pathway to Cures (the venture philanthropy fund for the National Bleeding Disorders Foundation) and others to re-imagine medicine based on the power of Engineered B cells. For more information, please visit us at and our LinkedIn page.
Yahoo
17-05-2025
- Business
- Yahoo
Be Biopharma Announces New Preclinical Data for BE-102, a B Cell Medicine for the Potential Treatment of Hypophosphatasia
Preclinical research demonstrates that a single administration of BE-102 provides continuous secretion of active alkaline phosphatase (ALP) in vivo out to 6 months No safety findings observed in long-term pharmacology studies Data presented at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting CAMBRIDGE, Mass., May 17, 2025--(BUSINESS WIRE)--Be Biopharma, Inc. ("Be Bio"), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today presented results from new preclinical research demonstrating a single administration of BE-102, a BCM for the potential treatment for Hypophosphatasia (HPP), produces continuous levels of active ALP long-term in vivo. The findings will be presented during an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting on Saturday, May 17, at 10:45 AM CT. HPP is a genetic disease caused by deficient ALP activity, resulting from pathogenic mutations in the ALPL gene, which leads to multi-systemic clinical complications including deficient bone mineralization. Enzyme replacement therapy (ERT) is the only approved treatment for HPP which requires frequent lifelong injections, and is only available for perinatal/infantile- and juvenile-onset forms of HPP. BE-102 was developed to address these limitations by providing continuous secretion of active ALP from a single infusion, with the flexibility to be titratable and re-dosable as needed. BE-102 is manufactured from primary human B cells by isolating, activating, and precision engineering with CRISPR/Cas9 followed by AAV-mediated delivery of a DNA donor template for the insertion of human ALPL gene into the CCR5 locus (a safe harbor locus) followed by expansion and differentiation in culture into ALP-secreting B lymphocyte lineage cells. "These studies demonstrate the potential of our B cell medicine platform to deliver B cell derived active ALP with durability out to six months," said Rick Morgan, Chief Scientific Officer of Be Biopharma. "BE-102 offers a novel and durable approach that may overcome the limitations of current enzyme therapy and does not require pre-conditioning, offering flexibility for re-dosing." The presentation highlights both in vivo and in vitro data supporting the target product profile for BE-102. In vivo studies were conducted in immune-deficient NOG-hIL6 mice, confirming long-term engraftment and continuous production of B cell derived active ALP (>175 days) following a single IV administration of BE-102. No BE-102 related adverse events have been observed across multiple in vivo studies. In vitro pharmacology data presented today demonstrates that BE-102 secretes active ALP, which is capable of rescuing calcium deposit inhibited by inorganic pyrophosphate (PPi), a potent inhibitor of bone mineralization and an ALP substrate which accumulates in people with HPP. Be Bio's in vitro and in vivo pharmacology and safety data established preclinical proof-of-concept that BE-102 has the potential to be a disease-modifying therapy for people with HPP by providing continuous secretion of ALP, with the flexibility to be titratable and re-dosable as needed. A robust package of preclinical studies is planned in anticipation of submission of an IND for a first-in-human clinical trial for people with HPP. About BE-102 BE-102 is a first-in-class BCM that has been engineered using artificial intelligence-guided protein design to modify primary human B cells to produce ALP, an enzyme deficient in people living with HPP. A single infusion of BE-102 has the potential to provide continuous secretion of therapeutic ALP with the flexibility to be titrated and/or re-dosed, if needed, and without the need for pre-conditioning. BE-102 has been selected as a Development Candidate and has the potential to transform the standard of care for people living with HPP. About Engineered B Cell Medicines – A New Class of Cellular Medicines The B cell is a powerful cell that produces thousands of proteins per cell per second at constant levels, and over decades. Precision genome editing can now be used to engineer B Cells that produce therapeutic proteins of interest, driving a new class of cellular medicines – Engineered B Cell Medicines (BCMs) – with the potential to be durable, allogeneic, re-dosable, and administered without pre-conditioning. The promise of BCMs could transform therapeutic biologics with broad application — across protein classes, patient populations and therapeutic areas. About Be Biopharma Be Biopharma ("Be Bio") is pioneering Engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to create a bold new class of cell therapies. Be Bio was founded in October 2020, and is backed by ARCH Venture Partners, Atlas Venture, RA Capital Management, Nextech, Alta Partners, Longwood Fund, Bristol Myers Squibb, Takeda Ventures, Seattle Children's Research Institute, Pathway to Cures (the venture philanthropy fund for the National Bleeding Disorders Foundation) and others to re-imagine medicine based on the power of Engineered B cells. For more information, please visit us at and our LinkedIn page. View source version on Contacts Investor Contact: ir@ Media Contact: media@ Sign in to access your portfolio
Business Recorder
10-05-2025
- Business
- Business Recorder
Harpo Hydropower Project: minister discusses reasons for delay
ISLAMABAD: Minister for Water Resources, Mian Muhammad Mueen Wattoo on Friday held a meeting on the Harpo Hydropower Project (HPP) and discussed reasons for its delay. The Harpo Hydropower Project is a 34.5 megawatt (MW), run-of-river power generation facility located in the Harpo Lungma area near Skardu. Utilizing the water flow from the Harpo Nullah — a tributary of the Indus River—it is designed to produce approximately 170 gigawatt-hours (GWh) of clean energy annually. The ground breaking ceremony was performed by the Prime Minister of Pakistan in 2024. The project is expected to significantly improve electricity supply in the region, benefiting over 350,000 residents and contributing to Pakistan's renewable energy goals. PM directs completion of two hydropower projects In April last year Prime Minister Shehbaz Sharif had directed that work on two hydropower projects in Attaabad and Harpo should be accelerated and sought action plan with regard to solar energy projects in Gilgit-Baltistan. He also formed a committee with respect to the solution of the problems faced by Gilgit-Baltistan following his meeting with Gulbar Khan, Chief Minister of Gilgit-Baltistan. The PM directed that the committee should submit its recommendations after consultation on all the issues facing Gilgit-Baltistan. The chief minister highlighted the strategic and developmental significance of the Harpo Hydropower Project for Gilgit-Baltistan and emphasized the need for swift and effective implementation. He directed that all legal and procedural formalities be completed at the earliest stage to preempt any legal or administrative obstacles, and to avoid future cost escalations. 'This project is of immense benefit to the people of Gilgit-Baltistan. We must expedite progress, ensure excellent delivery standards, and make transparency a cornerstone of this effort' the chief minister said. During the meeting, the committee discussed the issues related to the Harpo Hydropower Project, the financial mechanism with the foreign donor, AFD, and the financing gap in the PC-I. The minister instructed the concerned departments to take up the unresolved issues with the appropriate forums for immediate resolution and directed that all land-related records be thoroughly documented and maintained. The minister further emphasized that the entire process must remain transparent, with regular updates and access to information for stakeholders and the public. All financial disbursements, he stressed, must strictly follow the guidelines of the Government of Pakistan. The minister argued that the government's commitment to projects that promote equitable development, adding that 'these projects are not just infrastructure investments—they are pathways to prosperity. Delivering them efficiently is aligned with our national vision.'The meeting was attended by the federal secretary, Ministry of Water Resources, chief secretary Gilgit-Baltistan, chairman Wapda, and senior officials from relevant departments. Copyright Business Recorder, 2025
Express Tribune
10-05-2025
- Business
- Express Tribune
Harpo Hydropower fast-tracked for G-B
Listen to article A meeting of the High-Level Committee on the Harpo Hydropower Project (HPP) was convened today at the Ministry of Water Resources under the chairmanship of Federal Minister for Water Resources Mian Muhammad Mueen Wattoo. The Minister highlighted the strategic and developmental significance of the Harpo Hydropower Project for Gilgit-Baltistan and emphasised the need for its swift and effective implementation. He directed that all legal and procedural formalities be completed at the earliest stage to pre-empt any legal or administrative obstacles, and to avoid future cost escalations. "This project is of immense benefit to the people of Gilgit-Baltistan," the Minister stated. "We must expedite progress, ensure excellent delivery standards, and make transparency a cornerstone of this effort." The Harpo Hydropower Project is a 34.5 megawatt (MW), run-of-river power generation facility located in the Harpo Lungma area near Skardu. Utilising the water flow from the Harpo Nullah — a tributary of the Indus Riverit is designed to produce approximately 170 gigawatt-hours (GWh) of clean energy annually. The ground breaking ceremony was performed by the Honourable Prime Minister of Pakistan in 2024. The project is expected to significantly improve electricity supply in the region, benefiting over 350,000 residents and contributing to Pakistan's renewable energy goals. During the meeting, the committee discussed the issues related to the Project, the financial mechanism with the foreign donor, AFD, and the financing gap in the PC-I. The Minister instructed the concerned departments to take up the unresolved issues with the appropriate forums for immediate resolution and directed that all land-related records be thoroughly documented and maintained. Federal Minister further emphasised that the entire process must remain transparent, with regular updates and access to information for stakeholders and the public. All financial disbursements, he stressed, must strictly follow the guidelines of the Government of Pakistan. He reiterated the government's commitment to projects that promote equitable development.
